**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 5950**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (5): Colorectal cancer

**Current issues in locally advanced colorectal cancer treated by preoperative chemoradiotherapy**

Park IJ *et al*. Current issues in locally advanced CRC

In Ja Park, Chang Sik Yu

**In Ja Park, Chang Sik Yu,** Department of Colon and Rectal Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, South Korea

**Author contributions**: Yudesigned CS research; Park IJ performed research andwrote the paper.

**Correspondence to: Chang Sik Yu, MD, PhD,** **Professor,** Department of Colon and Rectal Surgery, Asan Medical Center, University of College of Medicine, 86 Asanbyeongwon-gil, Songpa-gu, Seoul 138-736, South Korea. csyu@amc.seoul.kr

**Telephone:** +82-2-30103494  **Fax:** +82-2-4749027

**Received:** September 28, 2013  **Revised:** November 26, 2013

**Accepted:** January 6, 2014

**Published online:**

**Abstract**

In patients with locally advanced rectal cancer, preoperative chemoradiotherapy has proven to significantly improve local control and cause lower treatment-related toxicity compared with postoperative adjuvant treatment. Preoperative chemoradiotherapy followed by total mesorectal excision or tumor specific mesorectal excision has evolved as the standard treatment for locally advanced rectal cancer. The paradigm shift from postoperative to preoperative therapy has raised a series of concerns however that have practical clinical implications. These include the method used to predict patients who will show good response, sphincter preservation, the application of conservative management such as local excision or “wait-and-watch” in patients obtaining a good response following preoperative chemoradiotherapy, and the role of adjuvant chemotherapy. This review addresses these current issues in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words**: Colorectal cancer; Rectal cancer; Preoperative chemoradiotherapy; Conservative; Response

**Core tip:** In the era of preoperative chemoradiotherapy for rectal cancer, issues such as treatment plan according to response which included application of organ preserving strategies, prediction of response, and role of adjuvant treatment were need to be discussed under circumstances that preoperative chemoradiotherpay spread widely as a standard treatment of rectal cancer.

Park IJ, Yu CS. Current issues in locally advanced colorectal cancer treated by preoperative chemoradiotherapy. *World J Gastroenterol* 2014;

**Available from:** URL: http://www.wjgnet.com/esps/

**DOI:** http://dx.doi.org/10.3748/wjg.v19.i0.0000

**INTRODUCTION**

Preoperative chemoradiotherapy (PCRT) has been used increasingly to treat locally advanced rectal cancer since it was proven to be beneficial in reducing the rate of local recurrence. A German trial[1] has reported that patients treated with PCRT had significantly lower local failure rates and toxicity rates than those receiving postoperative chemoradiotherapy (CRT), and PCRT was also found to produce a better outcome in terms of sphincter preservation. These findings led to a paradigm shift from postoperative to preoperative CRT so that PCRT has now become the standard treatment for cT3-4 and/or node-positive rectal cancer. This shift has however raised a series of concerns that have practical clinical implications such as a prediction of the responsiveness to PCRT, the application of conservative management such as local excision in patients obtaining a good response to this intervention, sphincter preservation, and the role of adjuvant chemotherapy. In this review, we discuss these issues.

**ORGAN PRESERVING STRATEGIES**

***Local excision***

Although the standard management of locally advanced rectal cancer treated by PCRT is radical surgical resection, conservative management (local excision or close observation) has been used in some cases. The local excision of rectal cancer has been employed as surgical procedure for patients with early rectal tumors limited to the mucosa and submucosa. In early T1 tumors without high risk features, full thickness local excision alone has been shown to produce comparable long-term outcomes to radical surgery[2]. Complete regression of the tumor was reported to occur in up to 20% of patients with rectal cancer after PCRT[3-6]. Some investigators have performed local excisions to avoid possible morbidities such as permanent stoma formation and functional impairments in patients who showed a good response to PCRT, with many studies reporting that such cases subsequently had acceptably low rates of local recurrence and long-term survival outcomes comparable to radical surgery[7-11]. The promising results from these studies have encouraged interest in the possibility of avoiding radical surgery in some patients after PCRT and thus preserving sexual and urinary function, sparing rectal function, and, in cases of low rectal cancer, avoiding permanent stoma (Table 1).

However, the interpretation of the above data is confounded by the predominantly retrospective nature of the studies on rectal cancer to date. Moreover, these earlier studies cannot be directly compared due to the significant heterogeneity with respect to patient and tumor characteristics resulting from a lack of consistent staging and selection criteria. In addition, no mesorectal lymphadenectomies were undertaken for these previous study cohorts and the lymph node stages were undefined. More importantly, the extent and quality of the local surgery is likely to have significantly varied between studies, depending on the individual techniques used and the skills of the surgeons involved.

One of the great uncertainties when conducting local surgery is the status of the mesorectal lymph nodes. Some studies have confirmed that there can be differential responses between the primary tumor and the mesorectal lymph nodes[12,13]. The proportion of lymph node metastases reported in pathological complete response (pCR) cases is low, with a median rate of 7% ranging from 2% to 11%[12,13,14]. The potential caveat of using mural response as the only criterion for selecting patients for local excision was highlighted in a retrospective study of 242 patients following PCRT[15]. The incidence of lymph node involvement was 3.2% in patients developing mural pCR (ypT0) compared to 11% for ypT1 tumors and increased further as the ypT stage increased (ypT2 = 29.2%; ypT3 = 37.3%). When nodal involvement is understaged and patients undergo local excision, the prognosis is poorer. Recently, the American College of Surgeons Oncology Group has completed the Z6041 phase II trial of patients with clinical T2N0 rectal cancer who received PCRT (total dose, 54 Gy) with capecitabine and oxaliplatin followed by transanal local excision 6 weeks after the completion of PCRT[16]. Of the 77 patients in that report who underwent local excision, 34 achieved a pCR (44%), 49 (64%) had ypT0-1, and 4 (5%) had ypT3 tumors. All but one patient had negative margins. Acute toxicity of at least grade 3 during PCRT occurred in 39% of these patients, and rectal pain was the most common postoperative complication. Colorectal Cancer Study Group in Korea also reported results of multicenter study for local resection after PCRT[17]. They reviewed 40 patients with cT2-3N0M0 treated with PCRT followed by local excision retrospectively. Among them, Four patients (7.5%) had recurrence [local recurrence (1 patient) and systemic metastasis (3 patients)]. The 3-year disease-free survival rate was 85.9%. Only pCR was a recurrence-related prognostic factor (*P* = 0.040). Based on these findings, a longer follow-up is clearly needed to assess the oncologic outcome. Moreover, local excisions need to be performed with great care for sub-group of patients and credible methods to measure the treatment response or remaining disease after PCRT are required.

***“Wait and watch”***

Possibly the other challenge for improving conservative treatment regimens for rectal cancers is to try to preserve not only the anal sphincter but also the whole organ. Habr-Gama is proposing a strategy comprising PCRT and “watch and wait” in cases of a clinical complete response (cCR) with no radical surgery[18]. Data from a Brazilian series have demonstrated excellent long-term local control and OS rates in patients developing cCR after PCRT[18]. The long-term outcome of the observation group (5 year OS 100%, DFS 92%) was similar to that of the resection group (5 year OS 88%, DFS 83%) with a histologic complete response.

The ability to identify patients with a cCR who are also likely to have a pCR would have major clinical implications. If such information were available and accurate, it could obviate the need for radical surgery and possibly prevent a permanent stoma in selected patients. The limitations of clinical assessments after PCRT were demonstrated in a prospective series of 94 patients who underwent an assessment with digital rectal examination (DRE) and sigmoidoscopy both prior to and after the completion of PCRT[19]. These clinical assessments underestimated the pathologic response in 73 patients and DRE was able to identify only three of 14 cases (21%) with a pCR. The overall concordance between clinical evaluation and actual pathologic response was only 22%[19]. In another retrospective review of 488 patients with rectal cancer following PCRT, the cCR rate for the entire cohort was 19%, but only 10% had a true pCR[20]. Glynne-Jones *et al*[21] reviewed 218 phase I/II and 28 phase III trials of preoperative radiotherapy or PCRT. They concluded that a clinical and/or radiological response does not sufficiently correlate with the pathologic response to recommend a ‘wait and see’ approach to surgery following preoperative therapy.

It is not surprising therefore that the Brazilian experience has generated intense debate with some investigators expressing concerns about employing a policy of watchful expectancy based entirely on the presence of cCR after PCRT[22,23].

It is notable that other investigators have been unable to reproduce these aforementioned results. Hughes *et al*[22] reported a 60% intrapelvic recurrence rate in 10 cases with a cCR and concluded that a ‘wait and see' policy could not be justified in T3 or 4 rectal cancers after PCRT. Nakagawa *et al*[24] also reported a high (80%) local recurrence rates and suggested that an exclusive PCRT approach is not safe for treating patients with low locally advanced rectal cancer. Such a strategy, however, could be of specific interest in elderly and vulnerable patients who are not fit for conventional surgery. It is possible that (full thickness) trans-anal local excision could be more relevant than observation alone after PCRT in such cases. Some phase II and III trials (ACOSOG Z 6041; GRECCAR 2; CONTEM 2) are currently ongoing to test this strategy.

**PREDICTION OF TREATMENT RESPONSE**

The response to PCRT differs among individual tumors and there currently is no effective method of predicting which patients will respond favorably to this treatment. Although positive responders to PCRT will experience the benefits of this intervention approach, patients who do not respond to PCRT will be exposed to unnecessary toxicities and surgery delay. It is therefore of the utmost importance to predict the treatment response and outcomes before initiating PCRT. Although a number of postsurgical prognostic factors have been proposed, patients with pCR after PCRT cannot at present be predicted by clinical examination or radiologic imaging procedures. The identification of basal resistance biomarkers could offer great help in this regard. Directed strategies that explore individual markers have not so far yielded clinically validated assays[25-27]. Past efforts to develop a predictive assay of tumor radio-sensitivity have been recently reviewed[28] and can be grouped into three categories: assays to determine intrinsic radiosensitivity (ex vivo determination of tumor survival fraction at 2 Gy)[29-32]; assays to determine tumor oxygen levels (electrodes to measure tumor pO2)[33,34]; and determination of tumor proliferative potential[35,36]. Unfortunately, although initial clinical data supported each of these approaches, none has become routine. A central reason for this has been that all of these approaches are highly impractical as a routine clinical application. The generation of high-throughput data sets has provided an opportunity to address the identification of biomarkers from a different perspective.

**ADJUVANT CHEMOTHERAPY IN ADDITION TO PCRT AND SURGERY**

There is no uniform agreement regarding the role of chemotherapy in addition to PCRT although current guidelines recommend additional adjuvant chemotherapy after PCRT regardless of the tumor response. Since most locally advanced rectal cancer patients have pathologically negative nodes following PCRT, some clinicians have argued that systemic therapy is not indicated. This argument is in part due to the lack of a proven survival benefit of chemotherapy in node negative colon cancer cases. The controversy is further illustrated by the fact that the European Organization for the Research and Treatment of Cancer (EORTC) is conducting a phase III trial in which patients are randomized to receive either 5-fluorouracil (5-FU) based chemotherapy or no further therapy following PCRT and radical resection.

The authors of the EORTC 22921 study reported that subgroups of patients achieving a pCR or who were downstaged to a ypT1-2 tumor category after preoperative radiation, benefited from adjuvant chemotherapy, whereas those with residual ypT3-4 disease did not[37]. These authors suggested the beneficial effects of adjuvant chemotherapy based on pathologic results, but they analyzed ypT and ypN categories separately. They also reported that adjuvant chemotherapy provided a benefit in patients who received a ypT downstage, but not in ypN0 or ypN-positive patients. Some data did not confirm results of EORTC 22921 especially in terms of the effect of adjuvant chemotherapy on patients achieving pCR[38, 39]. Chemotherapy is rarely indicated when the 5-year free-from recurrence rate exceeds 95%, which occurs in a complete pathological response. Considering the favorable outcome of patients with a complete response, survival outcomes with adjuvant chemotherapy is difficult to be improved than those of patients without adjuvant chemotherapy.

When evaluating subgroups of patients who may or may not benefit from adjuvant therapy after PCRT followed by resection, the benefit of adjuvant therapy for node-negative patients on final pathologic staging (ypN0) would be expected to be especially questionable. There is a paucity of information in the literature on whether adjuvant therapy improves survival for locally advanced rectal cancer patients with a stage ypN0 tumor. These findings are consistent with the suggestion by Fietkau *et al*[39] that postoperative chemotherapy may be unnecessary in ypN0 cases. Das *et al*[40] have insisted that postoperative chemotherapy may be of greater benefit for high-risk patients. However, their results are contrary to those of Janjan *et al*[41], who found a significant improvement in cancer-specific survival in response to PCRT and the addition of postoperative chemotherapy. In that study, it was suggested that patients who responded to 5-FU during PCRT would probably also respond to 5-FU-based postoperative chemotherapy.

Adjuvant chemotherapy for patients who do not show a good response to PCRT needs to be different from that administered to patients showing a good response to this treatment. Das *et al*[40] have recommended adjuvant FOLFOX for high-risk patients, and adjuvant FL or capecitabine for low-risk patients. This seems to be a reasonable approach to the postoperative adjuvant treatment of rectal cancer patients treated with PCRT. Until now, however, oxaliplatin has been the drug of focus in terms of outcome benefits as part of a preoperative multimodality treatment regimen[42-44]. The role of postoperative adjuvant chemotherapy following PCRT and radical resection for patients with locally advanced rectal cancer thus remains unclear.

**SPHINCTER PRESERVATION**

Avoiding permanent stoma is an important quality of life issue for rectal cancer patients[45]. An advantage of tumor shrinkage after PCRT is supposedly an increased chance of sphincter preservation[46,47]. However, this is a very complex issue involving the stage and location of the tumor, the patient habitus and desire, and the surgeon`s experience. Although an increase in the rate of sphincter preservation was reported in early PCRT trials, no such trials since 1980 have been able to demonstrate this. This may be due to the immediateness of the surgery after the end of a short-course of PCRT[48-51] which gives little opportunity for tumor shrinkage. However, despite an increased rate of pCR of up to 16–19% in the latest PCRT trials[42,52], no benefit has been evident in terms of the sphincter preservation rate.

Two randomized trials[1, 53] of preoperative and postoperative CRT for clinically resectable locally advanced rectal cancer have reported opposing results. In a German trial[1], of the 194 patients assessed by the surgeon before treatment as requiring APR, there was a significant improvement in sphincter preservation with preoperative therapy. However, in the National Surgical Adjuvant Breast and Bowel Project (NSABP) R-03 trial[53], based on a prospective assessment by the operating surgeon, there was no reported improvement in sphincter preservation (PCRT: 47.8%; postoperative CRT: 39.2; *P* = 0.227). The results of the NSABP R-03 trial, however, were obtained from only 267 of the 900 intended patients. The positive findings from the German trial were based on results from a sufficient number of patients, and the possibility of improved sphincter preservation by preoperative CRT remains one of the important potential benefits of this approach. In the recent Australian[54] trial where the two treatment arms were quite different (short course with immediate surgery vs. chemoradiotherapy and delayed surgery) there was a reported increase in sphincter preservation of 8% in the delayed surgery arm. However, this was not significant because the number of patients assessed was too small. Weiser *et al*[55] reported a benefit of PCRT in terms of sphincter preservation from a retrospective analysis of 148 rectal cancer patients (within 6 cm of the anal verge).

The pooled data from 19 trials[56] favors PCRT, although not in a statistically significant way, (0.94, 95%CI: 0.88-1.04) (Comparison 01:09). These data were borderline however in terms of homogeneity (*P* = 0.05), indicative of variations in the magnitude of effect across reports. In a recent review that analyzed the findings of 17 randomized trials the authors concluded that none of the neoadjuvant treatments tested could demonstrate an increase in the rate of sphincter-preserving surgery[57]. However, the effects of conservative treatments such as local excision or ”wait-and-watch“ on sphincter preservation were not considered in these analysis.

Until now, the evidence has been that an improved sphincter preservation benefit of PCRT was unclear. As described earlier, however, the link between PCRT and sphincter preservation needs to be evaluated with great care with consideration of tumor, patients and surgeon factors together. In addition, the effect of conservative management after PCRT need to be considered under condition the oncologic safety of this strategy is confirmed. The influence of PCRT on sphincter preservation needs to be re-evaluated under recent circumstances.

**CONCLUSION**

PCRT for locally advanced rectal cancer has been established as a standard treatment, but some issues regarding its practical application still need to be evaluated. In addition, an accurate prediction of the response to PCRT before administering this intervention, as well as an evaluation of nodal involvement after PCRT, remain important issues. An acceptable prediction of the response to PCRT should be integral to the decision making regarding an extension or selection of this treatment option.

**REFERENCES**

1 **Sauer R**, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R. Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* 2004; **351**: 1731-1740 [PMID: 15496622 DOI: 10.1056/NEJMoa040694]

2 **Winde G**, Nottberg H, Keller R, Schmid KW, Bünte H. Surgical cure for early rectal carcinomas (T1). Transanal endoscopic microsurgery vs. anterior resection. *Dis Colon Rectum* 1996; **39**: 969-976 [PMID: 8797643 DOI: 10.1007/BF02054683]

3 **Chan AK**, Wong A, Jenken D, Heine J, Buie D, Johnson D. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. *Int J Radiat Oncol Biol Phys* 2005; **61**: 665-677 [PMID: 15708244]

4 **Park JH**, Yoon SM, Yu CS, Kim JH, Kim TW, Kim JC. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. *Cancer* 2011; **117**: 3703-3712 [PMID: 21328328 DOI: 10.1002/cncr.25943]

5 **Garcia-Aguilar J**, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM; Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. *Ann Surg* 2011; **254**: 97-102 [PMID: 21494121]

6 **Smith KD**, Tan D, Das P, Chang GJ, Kattepogu K, Feig BW, Skibber JM, Rodriguez-Bigas MA. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. *Ann Surg* 2010; **251**: 261-264 [PMID: 19864936 DOI: 10.1097/SLA.0b013e3181bdfc27]

7 **Bujko K**, Sopylo R, Kepka L. Local excision after radio(chemo)therapy for rectal cancer: is it safe? *Clin Oncol (R Coll Radiol)* 2007; **19**: 693-700 [PMID: 17766096]

8 **Borschitz T**, Wachtlin D, Möhler M, Schmidberger H, Junginger T. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. *Ann Surg Oncol* 2008; **15**: 712-720 [PMID: 18163173 DOI: 10.1245/s10434-007-9732-x]

9 **Guerrieri M**, Baldarelli M, Organetti L, Grillo Ruggeri F, Mantello G, Bartolacci S, Lezoche E. Transanal endoscopic microsurgery for the treatment of selected patients with distal rectal cancer: 15 years experience. *Surg Endosc* 2008; **22**: 2030-2035 [PMID: 18553205]

10 **Kim CJ**, Yeatman TJ, Coppola D, Trotti A, Williams B, Barthel JS, Dinwoodie W, Karl RC, Marcet J. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. *Ann Surg* 2001; **234**: 352-38; discussion 352-38; [PMID: 11524588]

11 **Bonnen M**, Crane C, Vauthey JN, Skibber J, Delclos ME, Rodriguez-Bigas M, Hoff PM, Lin E, Eng C, Wong A, Janjan NA, Feig BW. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. *Int J Radiat Oncol Biol Phys* 2004; **60**: 1098-1105 [PMID: 15519780]

12 **Bujko K**, Richter P, Kołodziejczyk M, Nowacki MP, Kulig J, Popiela T, Gach T, Oledzki J, Sopyło R, Meissner W, Wierzbicki R, Polkowski W, Kowalska T, Stryczyńska G, Paprota K. Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders. *Radiother Oncol* 2009; **92**: 195-201 [PMID: 19297050 DOI: 10.1016/j.radonc.2009.02.013]

13 **Park IJ**, You YN, Skibber JM, Rodriguez-Bigas MA, Feig B, Nguyen S, Hu CY, Chang GJ. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy. *Dis Colon Rectum* 2013; **56**: 135-141 [PMID: 23303140]

14 **Jang TY**, Yu CS, Yoon YS, Lim SB, Hong SM, Kim TW, Kim JH, Kim JC. Oncologic outcome after preoperative chemoradiotherapy in patients with pathologic T0 (ypT0) rectal cancer. *Dis Colon Rectum* 2012; **55**: 1024-1031 [PMID: 22965400]

15 **Mignanelli ED**, de Campos-Lobato LF, Stocchi L, Lavery IC, Dietz DW. Downstaging after chemoradiotherapy for locally advanced rectal cancer: is there more (tumor) than meets the eye? *Dis Colon Rectum* 2010; **53**: 251-256 [PMID: 20173469]

16 **Garcia-Aguilar J**, Shi Q, Thomas CR, Chan E, Cataldo P, Marcet J, Medich D, Pigazzi A, Oommen S, Posner MC. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. *Ann Surg Oncol* 2012; **19**: 384-391 [PMID: 21755378 DOI: 10.1245/s10434-011-1933-7]

17 **Yu CS**, Yun HR, Shin EJ, Lee KY, Kim NK, Lim SB, Oh ST, Kang SB, Choi WJ, Lee WY; Colorectal Cancer Study Group, Korean Society of Coloproctology. Local excision after neoadjuvant chemoradiation therapy in advanced rectal cancer: a national multicenter analysis. *Am J Surg* 2013; **206**: 482-487 [PMID: 23849272 DOI: 10.1016/j.amjsurg.2013.01.042]

18 **Habr-Gama A**, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Silva e Sousa AH, Campos FG, Kiss DR, Gama-Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. *Ann Surg* 2004; **240**: 711-77; discussion 711-77; [PMID: 15383798 DOI: 10.1097/01.sla.0000141194.27992.32]

19 **Guillem JG**, Chessin DB, Shia J, Moore HG, Mazumdar M, Bernard B, Paty PB, Saltz L, Minsky BD, Weiser MR, Temple LK, Cohen AM, Wong WD. Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. *J Clin Oncol* 2005; **23**: 3475-3479 [PMID: 15908656 DOI: 10.1200/JCO.2005.06.114]

20 **Hiotis SP**, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, Wagman R, Saltz LB, Wong WD. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. *J Am Coll Surg* 2002; **194**: 131-15; discussion 131-15; [PMID: 11848629 DOI: 10.1016/S1072-7515(01)01159-0]

21 **Glynne-Jones R**, Wallace M, Livingstone JI, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified? *Dis Colon Rectum* 2008; **51**: 10-9; discussion 19-20 [PMID: 18043968]

22 **Hughes R**, Harrison M, Glynne-Jones R. Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy? *Acta Oncol* 2010; **49**: 378-381 [PMID: 20151936 DOI: 10.3109/02841860903483692]

23 **dos Santos LV**, dos Anjos Jácome AA, Cárcano FM, da Silveira Nogueira Lima JP, Serrano SV. Watch and wait policy remains experimental for the management of rectal cancer. *Colorectal Dis* 2010; **12**: 833 [PMID: 20497198 DOI: 10.1111/j.1463-1318.2010.02332.x]

24 **Nakagawa WT**, Rossi BM, de O Ferreira F, Ferrigno R, David Filho WJ, Nishimoto IN, Vieira RA, Lopes A. Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe? *Ann Surg Oncol* 2002; **9**: 568-573 [PMID: 12095973 DOI: 10.1007/BF02573893]

25 **Perou CM**, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. *Nature* 2000; **406**: 747-752 [PMID: 10963602 DOI: 10.1038/35021093]

26 **Sørlie T**, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci U S A* 2001; **98**: 10869-10874 [PMID: 11553815 DOI: 10.1073/pnas.191367098]

27 **Alizadeh AA**, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* 2000; **403**: 503-511 [PMID: 10676951]

28 **Torres-Roca JF**, Stevens CW. Predicting response to clinical radiotherapy: past, present, and future directions. *Cancer Control* 2008; **15**: 151-156 [PMID: 18376382]

29 **West CM**, Davidson SE, Roberts SA, Hunter RD. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. *Br J Cancer* 1993; **68**: 819-823 [PMID: 8398714 DOI: 10.1038/bjc.1993.434]

30 **West CM**, Davidson SE, Roberts SA, Hunter RD. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. *Br J Cancer* 1997; **76**: 1184-1190 [PMID: 9365167 DOI: 10.1038/bjc.1997.531]

31 **Buffa FM**, Davidson SE, Hunter RD, Nahum AE, West CM. Incorporating biologic measurements (SF(2), CFE) into a tumor control probability model increases their prognostic significance: a study in cervical carcinoma treated with radiation therapy. *Int J Radiat Oncol Biol Phys* 2001; **50**: 1113-1122 [PMID: 11483320]

32 **Björk-Eriksson T**, West C, Karlsson E, Mercke C. Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. *Int J Radiat Oncol Biol Phys* 2000; **46**: 13-19 [PMID: 10656366 DOI: 10.1016/s0360-3016(99)00373-9]

33 **Movsas B**, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, Hanks GE, Pollack A. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. *Urology* 2002; **60**: 634-639 [PMID: 12385924 DOI: 10.1016/S0090-4295(02)01858-7]

34 **Fyles A**, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. *J Clin Oncol* 2002; **20**: 680-687 [PMID: 11821448]

35 **Begg AC**, Haustermans K, Hart AA, Dische S, Saunders M, Zackrisson B, Gustaffson H, Coucke P, Paschoud N, Hoyer M, Overgaard J, Antognoni P, Richetti A, Bourhis J, Bartelink H, Horiot JC, Corvo R, Giaretti W, Awwad H, Shouman T, Jouffroy T, Maciorowski Z, Dobrowsky W, Struikmans H, Wilson GD. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. *Radiother Oncol* 1999; **50**: 13-23 [PMID: 10225552 DOI: 10.1016/S0167-8140(98)00147-9]

36 **Corvò R**, Giaretti W, Sanguineti G, Geido E, Orecchia R, Guenzi M, Margarino G, Bacigalupo A, Garaventa G, Barbieri M. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. *J Clin Oncol* 1995; **13**: 1843-1850 [PMID: 7636527]

37 **Collette L**, Bosset JF, den Dulk M, Nguyen F, Mineur L, Maingon P, Radosevic-Jelic L, Piérart M, Calais G; European Organisation for Research and Treatment of Cancer Radiation Oncology Group. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. *J Clin Oncol* 2007; **25**: 4379-4386 [PMID: 17906203 DOI: 10.1200/JCO.2007.11.9685]

38 **Capirci C**, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R, Coco C, Romano M, Mantello G, Palazzi S, Mattia FO, Friso ML, Genovesi D, Vidali C, Gambacorta MA, Buffoli A, Lupattelli M, Favretto MS, La Torre G. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. *Int J Radiat Oncol Biol Phys* 2008; **72**: 99-107 [PMID: 18407433 DOI: 10.1016/j.ijrobp.2007.12.019]

39 **Fietkau R**, Barten M, Klautke G, Klar E, Ludwig K, Thomas H, Brinckmann W, Friedrich A, Prall F, Hartung G, Küchenmeister U, Kundt G. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. *Dis Colon Rectum* 2006; **49**: 1284-1292 [PMID: 16758130 DOI: 10.1007/s10350-006-0570-x]

40 **Das P**, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Levy LB, Ellis LM, Crane CH. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. *Am J Clin Oncol* 2006; **29**: 219-224 [PMID: 16755173 DOI: 10.1097/01.coc.0000214930.78200.4a]

41 **Janjan NA**, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey JN, Lynch P, Ellis LM, Wolff R, Lenzi R, Abbruzzese J, Pazdur R, Hoff PM, Allen P, Brown T, Skibber J. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. *Am J Clin Oncol* 2001; **24**: 107-112 [PMID: 11319280 DOI: 10.1097/00000421-200104000-00001]

42 **Gérard JP**, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. *J Clin Oncol* 2010; **28**: 1638-1644 [PMID: 20194850 DOI: 10.1200/JCO.2009.25.8376]

43 **Gérard JP**, Chapet O, Nemoz C, Romestaing P, Mornex F, Coquard R, Barbet N, Atlan D, Adeleine P, Freyer G. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. *J Clin Oncol* 2003; **21**: 1119-1124 [PMID: 12637479 DOI: 10.1200/JCO.2003.10.045]

44 **Hospers GA**, Punt CJ, Tesselaar ME, Cats A, Havenga K, Leer JW, Marijnen CA, Jansen EP, Van Krieken HH, Wiggers T, Van de Velde CJ, Mulder NH. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. *Ann Surg Oncol* 2007; **14**: 2773-2779 [PMID: 17653805 DOI: 10.1245/s10434-007-9396-6]

45 **Krouse RS**, Herrinton LJ, Grant M, Wendel CS, Green SB, Mohler MJ, Baldwin CM, McMullen CK, Rawl SM, Matayoshi E, Coons SJ, Hornbrook MC. Health-related quality of life among long-term rectal cancer survivors with an ostomy: manifestations by sex. *J Clin Oncol* 2009; **27**: 4664-4670 [PMID: 19720920 DOI: 10.1200/JCO.2008.20.9502]

46 **Crane CH**, Skibber JM, Birnbaum EH, Feig BW, Singh AK, Delclos ME, Lin EH, Fleshman JW, Thames HD, Kodner IJ, Lockett MA, Picus J, Phan T, Chandra A, Janjan NA, Read TE, Myerson RJ. The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. *Int J Radiat Oncol Biol Phys* 2003; **57**: 84-89 [PMID: 12909219 DOI: 10.1016/S0360-3016(03)00532-7]

47 **Valentini V**, Coco C, Cellini N, Picciocchi A, Genovesi D, Mantini G, Barbaro B, Cogliandolo S, Mattana C, Ambesi-Impiombato F, Tedesco M, Cosimelli M. Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation. *Int J Radiat Oncol Biol Phys* 1998; **40**: 1067-1075 [PMID: 9539561 DOI: 10.1016/S0360-3016(97)00918-8]

48 **Sebag-Montefiore D**, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. *Lancet* 2009; **373**: 811-820 [PMID: 19269519 DOI: 10.1016/S0140-6736(09)60484-0]

49 **Påhlman L**, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. *Ann Surg* 1990; **211**: 187-195 [PMID: 2405793 DOI: 10.1097/00000658-199002000-00011]

50 Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. *N Engl J Med* 1997; **336**: 980-987 [PMID: 9091798 DOI: 10.1056/NEJM199704033361402]

51 **Kapiteijn E**, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. *N Engl J Med* 2001; **345**: 638-646 [PMID: 11547717 DOI: 10.1056/NEJMoa010580]

52 **Aschele C**, Pinto C, Cordio Sl. Preoperative fluorouracil (FU)- based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adjuvante Retto (STAR)-01 randomized phase III trial. *J Clin Oncol* 2009; **27**(Suppl 18): [abstr CRA4008]

53 **Roh MS**, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. *J Clin Oncol* 2009; **27**: 5124-5130 [PMID: 19770376 DOI: 10.1200/JCO.2009.22.0467]

54 **Ngan S**, fisher R, Goldstein D. A randomized trial comparing local recurrence rates between short-course and long-course preoperative radiotherapy for clinical T3 rectal cancer: an intergroup trial (TROG,AGITG,CSSANZ RACS). *J Clin Oncol* 2010; **28**(Suppl. 7): [abstr 3509]

55 **Weiser MR**, Quah HM, Shia J, Guillem JG, Paty PB, Temple LK, Goodman KA, Minsky BD, Wong WD. Sphincter preservation in low rectal cancer is facilitated by preoperative chemoradiation and intersphincteric dissection. *Ann Surg* 2009; **249**: 236-242 [PMID: 19212176 DOI: 10.1097/SLA.0b013e318195e17c]

56 **Wong RK**, Tandan V, De Silva S, Figueredo A. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. *Cochrane Database Syst Rev* 2007; (2): CD002102 [PMID: 17443515 DOI: 10.1002/14651858.CD002102.pub2]

57 **Gerard JP**, Rostom Y, Gal J, Benchimol D, Ortholan C, Aschele C, Levi JM. Can we increase the chance of sphincter saving surgery in rectal cancer with neoadjuvant treatments: lessons from a systematic review of recent randomized trials. *Crit Rev Oncol Hematol* 2012; **81**: 21-28 [PMID: 21377377 DOI: 10.1016/j.critrevonc.2011.02.001]

58 **Huh JW**, Jung EJ, Park YA, Lee KY, Sohn SK. Preoperative chemoradiation followed by transanal excision for rectal cancer. *J Surg Res* 2008; **148**: 244-250 [PMID: 17936793 DOI: 10.1016/j.jss.2007.08.010]

59 **Nair RM**, Siegel EM, Chen DT, Fulp WJ, Yeatman TJ, Malafa MP, Marcet J, Shibata D. Long-term results of transanal excision after neoadjuvant chemoradiation for T2 and T3 adenocarcinomas of the rectum. *J Gastrointest Surg* 2008; **12**: 1797-805; discussion 1805-6 [PMID: 18709419 DOI: 10.1007/s11605-008-0647-z]

60 **Kundel Y**, Brenner R, Purim O, Peled N, Idelevich E, Fenig E, Sulkes A, Brenner B. Is local excision after complete pathological response to neoadjuvant chemoradiation for rectal cancer an acceptable treatment option? *Dis Colon Rectum* 2010; **53**: 1624-1631 [PMID: 21178856 DOI: 10.1007/DCR.0b013e3181f5b64d]

61 **Perez RO**, Habr-Gama A, Lynn PB, São Julião GP, Bianchi R, Proscurshim I, Gama-Rodrigues J. Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution. *Dis Colon Rectum* 2013; **56**: 6-13 [PMID: 23222274]

**P-Reviewers:** De Ridder M, Kirshtein B **S-Editor:** Gou SX  **L-Editor: E-Editor:**

**Table 1 Local excision after preoperative chemoradiotherapy for rectal cancer *n* (%)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref** | **Year** | ***n*** | **inclusion** | **Complete remission**  | **Local recurrence**  | **Follow-up duration, mon** | **Overall survival (** |
| Kim *et al*[10]  | 2001 | 26 | cT2-3CR after PCRT | 17 (65.4) | 1 (3.8) | 19 | 100% |
| Bonnen *et al*[11] | 2004 | 26 | cT3N0 or N1CR after PCRT | 14 (53.8) | 2 (7.7) | 46 | 5 yr OS; 85% |
| Huh *et al*[58] | 2008 | 9 | cT2-3N0 or N1 | 4(44.4) | 1(11.1) | 91 | 10 yr OS; 88.9% |
| Nair *et al*[59] | 2008 | 44 | cT2-3N0 or N1CR after PCRT | 19 (43.2) | 4 (9.1) | 64 | 5 yr OS; 84 |
| Guerrieri *et al*[9] | 2008 | 145 | cT2-3N0 | 17 | 8 (4) | 81 | 100% (pT0-1)90% (pT2)77% (pT3) |
| Kundel *et al*[60]  | 2010 | 14 | CR after PCRT | All | 0 | 47 | 100% |
| Yu *et al*[17] | 2013 | 40 | cT2-3N0 | 19(47.5) | 4(7.5) | 38 | 3 yr DFS: 85.9% |
| Perez *et al*[61] | 2013 | 27 | cT2-3N0-2 | 3 (11.1) | 4(14.8) | 15 | 1 yr DFS: 68% |

CR: Complete remission; PCRT: Preoperative chemoradiotherapy (CRT); OS: Overall survival; DFS: Disese-free survival.